Drug news
CHMP recommends EU approval of Jentadueto (Boehringer) for Type 2 Diabetes
The EMA's CHMP recommend approval of Jentadueto (linagliptin plus metformin), from Boehringer, alongside diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. If approved by the EU the drug will provide a new, single-tablet treatment option for adults with Type 2 Diabetes who need to improve control of their blood glucose. The recommendation for approval was based on clinical trials that evaluated linagliptin and metformin as separate tablets. Bioequivalence of linagliptin/metformin HCl was demonstrated with co-administered linagliptin and metformin tablets in healthy subjects with Type 2 Diabetes.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins